GLP-1 drugs

Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
Once-weekly GLP-1 injectable approved for type 2 diabetesFDA has approved albiglutide (Tanzeum, GlaxoSmithKline), a once-weekly subcutaneous injectable for the treatment of adults with type 2 diabetes.
FDA approves once-weekly GLP-1 injectable for type 2 diabetesFDA approved albiglutide (Tanzeum, GlaxoSmithKline), a once-weekly subcutaneous injectable for the treatment of adults with type 2 diabetes. It helps to improve glycemic control, along with diet and exercise.
GLP-1 targeted therapy may help diabetes patientsThe role of ophthalmologists will become increasingly more vital in the management of type 2 diabetes as the numbers of patients with the disease is projected to double by 2030. Exenatide may prove to be an important adjunct to current oral anti-diabetes drugs.
Increased risk of pancreatitis reported with use of GLP-1 drugsPatients with type 2 diabetes mellitus taking glucagonlike peptide 1 (GLP-1)-based therapies may have a higher risk of acute pancreatitis, according to a recent report published in JAMA Internal Medicine.